Hao Wang
Johns Hopkins University · 412 works · 19,504 citations · h-index 46
Top works
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- Human Papillomavirus-related Carcinomas of the Sinonasal Tract
- Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells
- Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
- Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
- Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
- Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab
- The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
- Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
- Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
- Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
- CDK12 -Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
- Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma